CASCADIAN THERAPEUTICS, INC. (CASC) financial statements (2020 and earlier)

Company profile

Business Address 3101 WESTERN AVE.
SEATTLE, WA 98121
State of Incorp. DE
Fiscal Year End December 31
SIC 8731 - Commercial Physical and Biological Research (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2017
Q4
9/30/2017
Q3
6/30/2017
Q2
3/31/2017
Q1
12/31/2016
Q4
9/30/2016
Q3
6/30/2016
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments93102123126637281
Cash and cash equivalents17131336141751
Short-term investments778911090495530
Other undisclosed current assets2212211
Total current assets:95104124128647382
Noncurrent Assets
Property, plant and equipment1122112
Long-term investments and receivables811310   
Long-term investments811310   
Intangible assets, net (including goodwill)17171717171717
Goodwill17171717171717
Other noncurrent assets1111111
Total noncurrent assets:26302229191919
TOTAL ASSETS:1211331461578392101
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities11875876
Accounts payable2101111
Accrued liabilities6553332
Employee-related liabilities3221432
Other undisclosed current liabilities0000010
Total current liabilities:12985976
Noncurrent Liabilities
Liabilities, other than long-term debt 000000
Other liabilities 000000
Total noncurrent liabilities: 000000
Total liabilities:12985986
Stockholders' equity
Stockholders' equity attributable to parent109125138152748494
Common stock354354354354354354354
Additional paid in capital390388388387298297297
Accumulated other comprehensive loss(5)(5)(5)(5)(5)(5)(5)
Accumulated deficit(629)(613)(598)(584)(572)(562)(551)
Total stockholders' equity:109125138152748494
Other undisclosed liabilities and equity0000000
TOTAL LIABILITIES AND EQUITY:1211331461578392101

Income statement (P&L) ($ in millions)

12/31/2017
Q4
9/30/2017
Q3
6/30/2017
Q2
3/31/2017
Q1
12/31/2016
Q4
9/30/2016
Q3
6/30/2016
Q2
Revenues    0  
Operating expenses(17)(14)(15)(12)(11)(11)(30)
Operating loss:(17)(14)(15)(12)(11)(11)(30)
Nonoperating income
(Other Nonoperating income)
0000000
Loss from continuing operations before income taxes:(17)(14)(15)(11)(11)(11)(30)
Income tax benefit      7
Net loss attributable to parent:(17)(14)(15)(11)(11)(11)(24)
Other undisclosed net loss available to common stockholders, basic   (1) (1)(2)
Net loss available to common stockholders, diluted:(17)(14)(15)(12)(11)(12)(25)

Comprehensive Income ($ in millions)

12/31/2017
Q4
9/30/2017
Q3
6/30/2017
Q2
3/31/2017
Q1
12/31/2016
Q4
9/30/2016
Q3
6/30/2016
Q2
Net loss:(17)(14)(15)(11)(11)(11)(24)
Other comprehensive income (loss)(0)0(0)(0)(0)(0)0
Comprehensive loss:(17)(14)(15)(11)(11)(11)(24)
Other undisclosed comprehensive loss, net of tax, attributable to parent  (0)    
Comprehensive loss, net of tax, attributable to parent:(17)(14)(15)(11)(11)(11)(24)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: